Next Article in Journal
Resveratrol Sensitizes Tamoxifen in Antiestrogen-Resistant Breast Cancer Cells with Epithelial-Mesenchymal Transition Features
Next Article in Special Issue
The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients
Previous Article in Journal
Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
Previous Article in Special Issue
Early Lung Cancer Diagnosis by Biosensors
Int. J. Mol. Sci. 2013, 14(8), 15636-15654; doi:10.3390/ijms140815636
Article

Exploring the Glycosylation of Serum CA125

1
, 1
, 2
, 2
, 3,4
 and 1,*
1 NIBRT GlycoScience Group, National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Dublin 4, Ireland 2 The Mass Spectrometry Resource, Conway Institute, University College Dublin, Dublin 4, Ireland 3 UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland 4 Department of Pathology and Laboratory Medicine, St Vincent's University Hospital, Dublin 4, Ireland
* Author to whom correspondence should be addressed.
Received: 22 April 2013 / Revised: 15 July 2013 / Accepted: 16 July 2013 / Published: 26 July 2013
(This article belongs to the Special Issue Advances in Cancer Diagnosis)

Abstract

Ovarian cancer is the most lethal gynaecologic cancer affecting women. The most widely used biomarker for ovarian cancer, CA125, lacks sensitivity and specificity. Here, we explored differences in glycosylation of CA125 between serum from patients with ovarian cancer and healthy controls. We found differences between CA125 N-glycans from patient sera compared to controls. These include increases in core-fucosylated bi-antennary monosialylated glycans, as well as decreases in mostly bisecting bi-antennary and non-fucosylated glycans in patients compared to controls. Measurement of the glycosylated state of CA125 may therefore provide a more specific biomarker for patients with ovarian cancer.
Keywords: CA125; N-glycosylation; biomarker; ovarian cancer CA125; N-glycosylation; biomarker; ovarian cancer
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Saldova, R.; Struwe, W.B.; Wynne, K.; Elia, G.; Duffy, M.J.; Rudd, P.M. Exploring the Glycosylation of Serum CA125. Int. J. Mol. Sci. 2013, 14, 15636-15654.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert